Vertex Pharmaceuticals (VRTX) Intangibles (2009 - 2026)
Vertex Pharmaceuticals (VRTX) posted quarterly Intangibles of $418.5 million for Q1 2026, down 5.15% year-over-year from $441.2 million in Q1 2025, and down 1.34% quarter-over-quarter from $424.2 million in Q4 2025.
Vertex Pharmaceuticals (VRTX) Intangibles (2009 - 2026) Analysis & Trends
Vertex Pharmaceuticals' Intangibles history runs 18 years deep, the most recent figure standing at $418.5 million for Q1 2026.
- In Q1 2026, Intangibles fell 5.15% year-over-year to $418.5 million; the TTM figure through Mar 2026 stood at $418.5 million (down 5.15% YoY), while the FY2025 annual figure was $424.2 million, down 48.64% from the prior year.
- Intangibles for Q1 2026 stood at $418.5 million, down from $424.2 million in the prior quarter.
- The five-year high for Intangibles was $839.9 million in Q4 2023, with the low at $387.0 million in Q2 2022.
- The 5-year median for Intangibles is $603.6 million (2022), against an average of $595.5 million.
- The sharpest annual moves came in 2023 and 2025: Intangibles soared 55.97% in 2023, then sank 48.64% in 2025.
- Vertex Pharmaceuticals' Intangibles stood at $603.6 million in 2022, then soared by 39.15% to $839.9 million in 2023, then fell by 1.67% to $825.9 million in 2024, then tumbled by 48.64% to $424.2 million in 2025, then fell by 1.34% to $418.5 million in 2026.
- Business Quant data shows VRTX's Intangibles at $418.5 million in Q1 2026, $424.2 million in Q4 2025, and $429.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 412.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 266.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 63.28 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 60.96 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 93.49 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 412.80 Mn |
| Mar 31, 2026 | 418.50 Mn |
| Dec 31, 2025 | 424.20 Mn |
| Sep 30, 2025 | 429.80 Mn |
| Jun 30, 2025 | 435.50 Mn |
| Mar 31, 2025 | 441.20 Mn |
| Dec 31, 2024 | 825.90 Mn |
| Sep 30, 2024 | 831.60 Mn |
| Jun 30, 2024 | 837.50 Mn |
| Mar 31, 2024 | 834.90 Mn |
| Dec 31, 2023 | 839.90 Mn |
| Sep 30, 2023 | 603.60 Mn |
| Jun 30, 2023 | 603.60 Mn |
| Mar 31, 2023 | 603.60 Mn |
| Dec 31, 2022 | 603.60 Mn |
| Sep 30, 2022 | 603.60 Mn |
| Jun 30, 2022 | 387.00 Mn |
| Mar 31, 2022 | 400.00 Mn |
| Dec 31, 2021 | 400.00 Mn |
| Sep 30, 2021 | 400.00 Mn |